Last August, Children’s Hospital Los Angeles (CHLA) cardiologists confirmed the heart of a 27-week-old fetus suffered from a critical cardiac condition that prevented blood returning from the fetus’s lungs from circulating back into the body.

Vital Connect debuted the VitalPatch biosensor at the 2016 Healthcare Information and Management Systems Society (HIMSS) conference and exhibition, Feb. 29-March 4 in Las Vegas.

Avinger Inc. announced the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an enhanced version of its Pantheris lumivascular atherectomy system for the treatment of peripheral artery disease (PAD).

Philips announced four leading U.S. health systems have signed multi-year telehealth deals to implement the company’s remote intensive care unit (eICU) program.

IBM Watson Health announced plans Feb. 18 to acquire Truven Health Analytics, a leading provider of cloud-based healthcare data, analytics and insights, for $2.6 billion. Truven will bring more than 8,500 clients, including U.S. federal and state government agencies, employers, health plans, hospitals, clinicians and life sciences companies, to the IBM Watson Health portfolio.

Philips announced that it will introduce a next-generation monitoring solution for at-risk patients in low-acuity hospital settings, such as the general ward.

GE Healthcare announced two large systems integrators (SIs) and seven leading-edge independent software vendors (ISVs) are planning to move their digital solutions to the new GE Health Cloud. Designed exclusively for the healthcare industry and resting on the shoulders of GE’s Predix platform, the GE Health Cloud will ultimately connect more than 2 million imaging machines worldwide, including 500,000 GE Healthcare devices.

Nexstim Plc announced that the Data Safety Monitoring Board (DSMB), an independent committee of experts monitoring the Phase III stroke therapy NICHE trial, has reviewed the interim analysis data. The DSMB notes that the pre-specified stopping criteria for futility have been met and therefore the trial will not meet its primary endpoint. However, the DSMB further notes that they acknowledge that the treatments and enrolment have been completed. They recommend that the study team and subjects remain blinded and data collection be completed.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now